Advertisement

The ASCO Post Newsreels help clinicians stay up to date on news in the world of clinical oncology and hematology. Newsreels feature leading authorities presenting high-impact clinical findings at major oncology meetings throughout the year.



Showing All Recent Newsreels Videos


Advertisement

2021 Gastrointestinal Cancers Symposium

Zev A. Wainberg, MD, on Gastric/Gastroesophageal Junction Adenocarcinoma: Bemarituzumab and FOLFOX

Wasat Mansoor, MBChB, PhD, on Esophageal Cancer: Quality of Life With Pembrolizumab and Chemotherapy

Afsaneh Barzi, MD, PhD, on Disparities in Access to Screening and Treatment of GI Cancers

Rutika Mehta, MD, MPH, on Gastric Cancer: Adjuvant Chemotherapy With S-1 and Docetaxel

Romain Cohen, MD, PhD, on Colon Cancer: Prognostic Value of Tumor Deposits

Kai-Keen Shiu, MD, PhD, on Colorectal Cancer: Pembrolizumab vs Chemotherapy for Microsatellite Instability–High Disease

Milind M. Javle, MD, on Cholangiocarcinoma: Treatment With Infigratinib

Tenna V. Henriksen, PhD Candidate, on Colorectal Cancer: Circulating Tumor DNA Analysis to Improve Treatment

Richard S. Finn, MD, on HCC: Atezolizumab Plus Bevacizumab vs Sorafenib

Talia Golan, MD, on Pancreatic Cancer: Olaparib for BRCA-Mutated Disease

Matthew H.G. Katz, MD, on Pancreatic Cancer: Preoperative mFOLFIRINOX for Resectable Disease

Andrew X. Zhu, MD, PhD, on IDH1-Mutant Cholangiocarcinoma: Ivosidenib vs Placebo

Thierry André, MD, on Mismatch Repair–Deficient Solid Cancers: Safety and Efficacy of Dostarlimab

Rocio Garcia-Carbonero, MD, on Treating Neuroendocrine Tumors of Nonpancreatic Origin With Octreotide Acetate and Axitinib


2020 San Antonio Breast Cancer Symposium

Chirag Shah, MD, on Assessing DCIS Recurrence Risk

Debra A. Pratt, MD, on Time to Completion of Breast Cancer Treatment and Survival

Nadia Harbeck, MD, on Early Breast Cancer: Endocrine Therapy After Preoperative Treatment

Joseph A. Sparano, MD, on HR+, HER2– Breast Cancer: Individualizing Prognosis and Predicting Treatment Success

Patricia A. Ganz, MD, on Younger Breast Cancer Survivors: Managing Depression

Sara A. Hurvitz, MD, on Triple-Negative Breast Cancer: Sacituzumab Govitecan and Chemotherapy

Lee S. Schwartzberg, MD, on HER2– HR+ Breast Cancer: Tesetaxel and Capecitabine

Roisin M. Connolly, MD, on HR+ Advanced Breast Cancer: Endocrine Therapy and Entinostat

Joyce V. Lee, PhD, on Triple-Negative Breast Cancer: MYC as a Predictor of Treatment Response

Sibylle Loibl, MD, on HR+ HER2– Primary Breast Cancer: Palbociclib and Endocrine Therapy

Elizabeth A. Mittendorf, MD, PhD, on Her Plenary Lecture: Local Regional Management Following Neoadjuvant Therapy

Ann H. Partridge, MD, MPH, on ER+, HER2– Breast Cancer: More Effective Treatments Needed


2020 ASH Annual Meeting & Exposition

Ann-Kathrin Eisfeld, MD, on AML in Black Patients: Racial Disparities in Survival Outcomes

Corey Cutler, MD, MPH, on MDS: Evaluating Treatments in Older Patients With Advanced Disease

Emmanuel Bachy, MD, PhD, on Peripheral T-Cell Lymphoma: Romidepsin Plus CHOP

Radhika Gangaraju, MD, and Smita Bhatia, MD, MPH, on Coronary Heart Disease Risk in Blood or Marrow Transplant Survivors

Curtis Lachowiez, MD, on AML: Venetoclax in Combination With Standard Intensive Induction/Consolidation Therapy

Sagar Lonial, MD, on CAR T-Cell Therapies for Myeloma: Novel Approaches and Longer-Term Follow-up Data

Jyoti Nangalia, MBBChir, on MPN: A New Paradigm for the Development of Blood Cancer?

David T. Teachey, MD, on Pediatric Leukemia and Lymphoma: New Findings on Cranial Radiation and Bortezomib

Paul G. Richardson, MD, on Multiple Myeloma: Roundup of Three Key Studies

Matthew S. Davids, MD, on CLL/SLL: New Data on Ibrutinib, Venetoclax, and Rituximab Therapies

Caron A. Jacobson, MD, on Treating Large B-Cell Lymphoma With Axicabtagene Ciloleucel

Ari M. Melnick, MD, on Activated B-Cell­–Like DLBCL: Gain-of-Function Mutations and Resistance to Ibrutinib

Meletios A. Dimopoulos, MD, on Multiple Myeloma: Daratumumab, Pomalidomide, and Dexamethasone

Andrew D. Zelenetz, MD, PhD, on Mantle Cell Lymphoma: Immunochemotherapy Plus Lenalidomide

Andrew D. Zelenetz, MD, PhD, on Mantle Cell Lymphoma: Expert Perspective on Key Clinical Trials

Hassan Awada, MD, on AML and Machine Learning: Improving Prognostication

Jorge E. Cortes, MD, on CML: Expert Perspective on Key ASH Abstracts

Farhad Ravandi, MD, on AML: Novel Combination Therapies for Newly Diagnosed Disease

Nitin Jain, MD, on B-Cell ALL: Expert Perspective on Key CAR T-Cell Treatment Advances

Steven M. Horwitz, MD, on T-Cell Lymphoma: Update on Allogeneic Hematopoietic Transplant

Tycel J. Phillips, MD, on Marginal Zone Lymphoma: Efficacy and Safety of Parsaclisib

Steven M. Horwitz, MD, on PTCL: Update on Efficacy of Duvelisib Dose Optimization

Christian Marinaccio, PhD Candidate: Genetic Driver May Play a Role in Progression of Myeloproliferative Neoplasms to AML

Lena E. Winestone, MD, MSHP, on Health-Care Disparities in Hematologic Cancers: Real-World Data

Sara Zarnegar-Lumley, MD, on AML: Prognostic Effects of IDH Mutations


Quantitative Imaging Workshop XVII

Daniel G. Petereit, MD, on Disparities in Lung Cancer Care for Northern Plains American Indians

Fred R. Hirsch, MD, PhD, on Early-Stage Lung Cancer: Targeted Treatment and Screening

David Yankelevitz, MD, on Early-Stage Lung Cancer: Renewed Interest in Combined-Modality Treatment

James L. Mulshine, MD, on Meeting Highlights: Advancing Quantitative Low-Dose CT Imaging in Thoracic Disease

Mary Pasquinelli, DNP, APRN, FNP-BC, on Addressing Lung Cancer Care Equity in Vulnerable Communities


2020 ASTRO Annual Meeting

Neha Vapiwala, MD, on Prostate Cancer: Imaging and the Decision to Treat With Radiation

Arjun Sahgal, MD, on Reducing the Pain of Spinal Metastases: SBRT vs Palliative Radiotherapy

Juliane Hörner-Rieber, MD, on Breast Cancer: Boosting Intensity-Modulated and Conventional Radiotherapies

Paul Sargos, MD, on Prostate Cancer: Adjuvant or Early Salvage Radiotherapy Plus Androgen Deprivation

Youssef Zeidan, MD, PhD, on HER2-Positive Breast Cancer: Deintensifying Radiation Therapy

Cynthia Menard, MD, on Prostate Cancer: PSMA PET- and CT-Guided Intensification of Radiotherapy

Daniel E. Spratt, MD, on Prostate Cancer: Short-Term Adjuvant vs Neoadjuvant Hormone Therapy

Daniel E. Spratt, MD, on Prostate Cancer: Relugolix vs Leuprolide

Alphonse G. Taghian, MD, PhD, on Irradiation for Breast Cancer: Defining the Optimal Dose

Vinai Gondi, MD, on Glioblastoma: Dose Intensification, IMRT, Standard Radiotherapy, and Temozolomide

Jing Li, MD, PhD, on Brain Metastases: Stereotactic Radiosurgery vs Whole-Brain Radiation Therapy

Justin Oh, MD, on Prostate Cancer: Brachytherapy vs External-Beam Radiation Therapy

Jeff M. Michalski, MD, MBA, on Medulloblastoma and Radiation Treatment in Pediatric Patients


2020 ASCO Quality Care Symposium

Melissa K. Accordino, MD, on Breast Cancer Care Delivery: Impact of the COVID-19 Pandemic

Veena Shankaran, MD, on Colorectal Cancer: Cumulative Financial Hardship of Treatment

Joseph M. Unger, PhD, on Patient Interest in Clinical Trial Enrollment: A New Analysis

Katherine Enright, MD, MPH, on Improving the Quality of Oral Cancer Drug Delivery

Marie A. Flannery, PhD, and Eva Culakova, PhD, on Managing Symptoms in Older Adults With Advanced Cancer

Anne M. Barry-Weers, RN, on Decreasing Hospitalizations for Patients Receiving IV Chemotherapy

Cardinale B. Smith, MD, PhD, on Telehealth Disparities During the COVID-19 Pandemic

Cardinale B. Smith, MD, PhD, on Redesigning Care Coordination From the Patient’s Perspective

James D. Murphy, MD, on Opioid Use Among Patients With Cancer


ESMO Virtual Congress 2020

Masahiro Tsuboi, MD, on NSCLC: Adjuvant Osimertinib in EGFR-Mutated Disease

Toni K. Choueiri, MD, on RCC: Nivolumab Plus Cabozantinib vs Sunitinib in First-Line Treatment

Mansoor Raza Mirza, MD, on Endometrial Cancer: Palbociclib Plus Letrozole in ER-Positive Disease

Andreas Schneeweiss, MD, on Breast Cancer: Comparing Neoadjuvant Chemotherapy With Paclitaxel, Doxorubicin, and Carboplatin

Erika P. Hamilton, MD, on Breast Cancer: Abemaciclib With or Without Tamoxifen in HR-Positive, HER2-Negative Metastatic Disease

Ezra E.W. Cohen, MD, on Head and Neck Cancer: Avelumab and Chemoradiotherapy in Locally Advanced Disease

David S. Hong, MD, on NSCLC: Durability of Clinical Benefit and Biomarkers in Patients Treated With Sotorasib

Sumanta K. Pal, MD, on Renal Cell Carcinoma: Cabozantinib Plus Atezolizumab as First-Line Therapy

Nicholas D. James, PhD, MBBS, on Prostate Cancer: Abiraterone Acetate Plus Prednisolone for Hormone-Naive Disease

Stephen R.D. Johnston, MD, PhD, on Early Breast Cancer: Abemaciclib in High-Risk Disease

Thierry Andre, MD, on Colorectal Cancer: Health-Related Quality of Life With Pembrolizumab vs Chemotherapy

Paolo A. Ascierto, MD, on Melanoma: Sequencing Targeted Treatments and Immunotherapy

Benjamin Besse, MD, PhD, on NSCLC: Neoadjuvant Atezolizumab for Resectable Disease

Cécile Le Pechoux, MD, on NSCLC: Comparing Postoperative Radiotherapy With No Radiotherapy

Erica L. Mayer, MD, MPH, on Early Breast Cancer: Palbociclib With Endocrine Therapy vs Endocrine Therapy Alone

Aditya Bardia, MD, MPH, on Triple-Negative Breast Cancer: Sacituzumab Govitecan vs Treatment of Physician’s Choice

Alexander M. Eggermont, MD, PhD, on Melanoma: Pembrolizumab vs Placebo After Complete Resection

Lisa A. Carey, MD, on Triple-Negative Breast Cancer: Paclitaxel, Nab-paclitaxel, and Atezolizumab in IMpassion Trials

Monika K. Krzyzanowska, MD, MPH, on Early-Stage Breast Cancer: Ambulatory Toxicity Management in the AToM Study

Jeffrey S. Weber, MD, PhD, on Melanoma: Adjuvant Nivolumab vs Ipilimumab

Andreas du Bois, MD, PhD, on Ovarian Cancer: Niraparib, Trabectedin Plus Doxorubicin, Platinum, and Carboplatin


IASLC World Conference on Lung Cancer

Paul Baas, MD, PhD, on Mesothelioma: First-Line Nivolumab Plus Ipilimumab vs Chemotherapy

Misako Nagasaka, MD, on NSCLC: Sintilimab, Pemetrexed, and Platinum as First-Line Therapy

Leora Horn, MD, on NSCLC: Ensartinib vs Crizotinib in ALK–Positive Disease

Marina C. Garassino, MD, on COVID-19 and Thoracic Malignancies: TERAVOLT Registry


ASCO20 Virtual Education Program

Matti S. Aapro, MD, on Curing Sarcomas: An Expert Review


AACR Virtual Meeting: COVID-19 and Cancer

Arthur L. Caplan, PhD, on Ethics, Cancer, and COVID-19

Karen E. Knudsen, MBA, PhD, on the Challenges of Using Telehealth in Cancer Care

Catherine H. Marshall, MD, MPH, on Promoting Recovery From COVID-19 Infection With Endocrine Therapy

Antoni Ribas, MD, PhD, on AACR Virtual Meeting: COVID-19 and Cancer Highlights

Nancy E. Davidson, MD, on Bringing Patients With Cancer Back to the Clinic During the COVID-19 Pandemic

Jessica Y. Islam, PhD, MPH, on COVID-19 Preventive Behaviors Among Cancer Survivors

Gabriella Pravettoni, PhD, on COVID-19 and Cancer: Psychological Effects on Patients and Oncologists

Dafna Bar-Sagi, PhD, on COVID-19: How Cancer Researchers Can Help Address the Challenges


First International Summit on Interventional Pharmacoeconomics

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Welcome and Introduction to Vi3C

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Opening Session Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Varsha Gandhi, PhD, on Ibrutinib

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Opportunities to Optimize Cancer Policies Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

David A. Hyman, MD, JD, on Inclusive Shared Savings

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Deborah Collyar: What's In It for Patients?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics


AACR Virtual Annual Meeting 2020 II

Nasser K. Altorki, MD, on Lung Cancer: Radiotherapy and Immune Checkpoint Blockade in the Neoadjuvant Setting

Adam C. Palmer, PhD, on Immune Checkpoint Inhibitors: Additive to or Synergistic With Other Treatments?

Stacey A. Fedewa, PhD, on Cancers in Younger Populations: Current Trends

Alfonso Bencomo Álvarez, PhD, on ALL, AML, and CML: Survival for Hispanic Patients Living Near the US/Mexico Border

Antoni Ribas, MD, PhD, on Racism and Racial Inequities in Cancer Research

Xavier Llor, MD, PhD, on Colorectal Cancer: Why Are More Younger People Being Affected?

Silvia Formenti, MD, on Testing Radiation and Immune Checkpoint Blockade in Different Tumor Settings

Ramaswamy Govindan, MD, on Differences Among Male and Female Patients With Lung Cancer

Ralph R. Weichselbaum, MD, on Radiotherapy and Immunotherapy in Oligometastatic Disease

Antoni Ribas, MD, PhD, on Turning Science Into Life-Saving Care

Kala Visvanathan, MD, on Ovarian Cancer: Lowering Mortality With Lipophilic Statins

Robert A. Winn, MD, on the Impact of COVID-19 on Cancer Care Among Racial and Ethnic Minorities

Elizabeth H. Stover, MD, PhD, on Ovarian Cancer: Nivolumab Plus Bevacizumab for Relapsed Disease


EHA25 Virtual

Abhishek Maiti, MBBS, on AML: Decitabine and Venetoclax vs Intensive Chemotherapy

Courtney D. DiNardo, MD, on AML: Venetoclax and Azacitidine for Treatment-Naive Patients

Anthony Moorman, PhD, on ALL: Improving Outcomes With a Tyrosine Kinase Inhibitor Plus Chemotherapy

Michael J. Dickinson, MBBS, DMedSc, on Non-Hodgkin Lymphoma: Early Study Findings With Novel T-Cell–Engaging Bispecific Antibody

Elias Jabbour, MD, on Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Venetoclax and Navitoclax in Relapsed or Refractory Disease

John C. Byrd, MD, on CLL/SLL: Acalabrutinib in Treatment-Naive Patients

Elizabeth H. Phillips, MD, on DLBCL: Inotuzumab Ozogamicin Plus Chemotherapy in Front-Line Setting

Efstathios Kastritis, MD, on Amyloidosis: Daratumumab Plus Cyclophosphamide, Bortezomib, and Dexamethasone

Jorge E. Cortes, MD, on Chronic Phase CML: Comparing Three Starting Doses of Ponatinib

Arnon P. Kater, MD, PhD, on CLL: Efficacy of Venetoclax in Relapsed or Refractory Disease

Andrew H. Wei, MBBS, PhD, on AML: Venetoclax Plus Cytarabine in Older Patients


ASCO20 Virtual Scientific Program

Welcome to This Year’s Meeting: A Message From ASCO President Howard A. Burris III, MD, FACP, FASCO

David C. Fajgenbaum, MD, MBA, on Chasing His Cure: A Physician Is Battling His Disease and Beating the Odds

Richard L. Schilsky, MD, on This Year’s Practice-Changing Findings

Roy S. Herbst, MD, PhD, on NSCLC: Osimertinib in Stage IB–IIIA EGFR Mutation–Positive Disease

Christopher Sweeney, MBBS, and Thomas Powles, MD, PhD, on Urothelial Cancer: The JAVELIN Bladder 100 Study on Avelumab vs Best Supportive Care

Seema A. Khan, MD, MPH, on Metastatic Breast Cancer: Systemic vs Locoregional Therapies

Shaji Kumar, MD, on Multiple Myeloma: Phase III Results on Carfilzomib, Lenalidomide, Bortezomib, and Dexamethasone

Thierry André, MD, on Colorectal Cancer: Pembrolizumab vs Chemotherapy for Metastatic Disease

Andres Poveda, MD, on Ovarian Cancer: Assessing Maintenance Olaparib

Leora Horn, MD, on Thoracic Cancer and COVID-19: How Type of Cancer Therapy May Affect Survival

Merry-Jennifer Markham, MD: Perspectives on Three Abstracts From the ASCO Cancer Communications Chair

Metastatic Urothelial Cancer: A Conversation on State-of-the-Art Treatment Before the ASCO20 Virtual Scientific Program

Howard A. Burris III, MD, FACP, FASCO, on Highlights of the ASCO20 Virtual Scientific Program

Nancy U. Lin, MD, on Metastatic Breast Cancer: Tucatinib, Trastuzumab, and Capecitabine

Scott Kopetz, MD, PhD, on Colorectal Cancer: Encorafenib Plus Cetuximab With or Without Binimetinib

Fatima Cardoso, MD, on Breast Cancer: MammaPrint as Guidance for Adjuvant Chemotherapy

Jeffrey A. Meyerhardt, MD, MPH, on Colon Cancer: Celecoxib and FOLFOX for Stage III Disease

Michael S. Hofman, MBBS, on Prostate Cancer: LuPSMA vs Cabazitaxel in Metastatic Castration-Resistant Disease

David R. Wise, MD, PhD, on Novel Biomarkers in Prostate Cancer: Is Tissue the Issue?

Rana R. McKay, MD, on Prostate Cancer: Intense Androgen-Deprivation Therapy Before Radical Prostatectomy

Alberto F. Sobrero, MD, on Colon Cancer: Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy for Stage III Disease

Neal D. Shore, MD, on Prostate Cancer: Relugolix vs Leuprolide for Advanced Disease

Cynthia X. Ma, MD, PhD, on Breast Cancer: Neoadjuvant Endocrine Treatment for ER-Positive, HER2-Negative Disease

Eric Jonasch, MD, on a Novel Therapy for Von Hippel-Lindau Disease–Associated RCC

Meletios A. Dimopoulos, MD, on Multiple Myeloma: Selinexor, Bortezomib, and Dexamethasone for Previously Treated Patients

Sara A. Hurvitz, MD, on Breast Cancer: Four Major Studies on Trastuzumab, Pertuzumab, Anthracyclines, and Chemotherapy De-escalation

Michael J. Morris, MD, on Prostate Cancer: Impact of PSMA-Targeted Imaging on Clinical Management

Tingyan Shi, MD, PhD, on Ovarian Cancer: Secondary Cytoreductive Surgery for Recurrent Disease

Daniel P. Petrylak, MD, on Prostate Cancer: First-in-Human Study of ARV-110 Shows Antitumor Activity

Ursula A. Matulonis, MD, on Ovarian Cancer: Roundup of Studies on Olaparib, Cediranib, Mirvetuximab Soravtansine, Bevacizumab, and Pembrolizumab

Lourdes Gil Deza on Caring for Transgender Patients With Cancer

Mikkael A. Sekeres, MD, on MDS, CMML, or AML: Pevonedistat and Azacitidine

Farhad Ravandi-Kashani, MD, on Acute Myeloid Leukemia: AMG 330 in Patients With Relapsed or Refractory Disease

Reshma Jagsi, MD, DPhil, and Narjust Duma, MD, on Diversity in Oncology: A Discussion of Evidence-Based Transformation

Jeremy L. Warner, MD, on the Clinical Impact of COVID-19 on Patients With Cancer

Douglas B. Johnson, MD, on Melanoma: Clinical Trials Update on PD-1 and CTLA-4 Blockade

Christopher Nutting, MD, PhD, on Head and Neck Cancer: Dysphagia-Optimized vs Standard IMRT

Rachel E. Sanborn, MD, on NSCLC: Maximizing the Benefits of Targeted Therapies for EGFR-Mutated Disease

Nirav Niranjan Shah, MD, on DLBCL: Autologous Transplant vs CAR T-Cell Therapy

Suresh S. Ramalingam, MD, on NSCLC: Nivolumab Plus Ipilimumab vs Chemotherapy

Lakshmi Nayak, MD, on Primary CNS Lymphoma: The Search for Optimal First-Line Treatment

Egbert F. Smit, MD, PhD, on NSCLC: Treatment With Fam-trastuzumab Deruxtecan

Peter Reichardt, MD, PhD, on GIST: Adjuvant Imatinib for High-Risk Disease

Parameswaran Hari, MD, on Multiple Myeloma: Post-Autologous Hematopoietic Cell Transplantation Strategies in Upfront Treatment

Nikhil C. Munshi, MD, on Multiple Myeloma: Idecabtagene Vicleucel in Patients With Relapsed or Refractory Disease

Patricia Pautier, MD, on Leiomyosarcoma: Doxorubicin and Trabectedin for First-Line Treatment

Paul G. Richardson, MD, on Multiple Myeloma: First-in-Human Study of the Novel Agent CC-92480

Parameswaran Hari, MD, on Multiple Myeloma: Expert Commentary on Four Key Abstracts

Sarah A. Holstein, MD, PhD, on Multiple Myeloma: Expert Perspective on Five Key ASCO20 Abstracts

Howard A. Burris III, MD, FACP, FASCO, on the ASCO20 Virtual Scientific Program: After Action Report

Eric Zhou, PhD, on Insomnia in Young Cancer Survivors: Online Program May Improve Quality of Life


AACR Virtual Annual Meeting 2020 I

Lajos Pusztai, MD, PhD, on Breast Cancer: I-SPY2 Trial on Durvalumab, Olaparib, and Paclitaxel

Steven J. O’Day, MD, on Triple-Negative Breast Cancer: Clinical Benefit With Pembrolizumab Plus Imprime PGG

Grant A. McArthur, MBBS, PhD, on Melanoma: IMspire150 Trial of Atezolizumab, Cobimetinib, and Vemurafenib

Ryan J. Sullivan, MD, on Advanced Solid Tumors: Antitumor Activity With COM701 Plus Nivolumab

Kimlin T. Ashing, PhD, on Tobacco and Vape Shops in Neighborhoods With Lower-Income and Minority Populations

Byoung Chul Cho, MD, PhD, on NSCLC: Genetic Mutations and Immunotherapy vs Chemotherapy in KEYNOTE-042

Nickolas Papadopoulos, PhD, on Liquid Biopsy to Screen for Multiple Cancer Types

Edward B. Garon, MD, on NSCLC: Long-Term Use of Pemetrexed Plus Platinum With Pembrolizumab

Edward B. Garon, MD, on Metastatic NSCLC: GEOMETRY mono-1 Trial of Capmatinib

Jennifer K. Litton, MD, on Breast Cancer: EMBRACA Trial on Talazoparib vs Chemotherapy

Qi Liu, PhD, on NSCLC: Pneumonitis, Immunotherapy, and Chemotherapy

Andrew X. Zhu, MD, PhD, on Hepatocellular Carcinoma: Atezolizumab Combined With Bevacizumab


NCCN 2020 Virtual Annual Conference

Elizabeth Reed, MD, on Helping Providers in Rural Areas Meet the Needs of Younger Patients With Breast Cancer

William J. Gradishar, MD, on Innovating Pathways for Patient Self-Management in Breast Cancer

Karen Wonders, PhD, on Benefits of Exercise During Cancer Treatment

Apar Kishor Ganti, MD, on NSCLC: Real-World Adherence and Persistence of ALK Inhibitors

Sara A. Hurvitz, MD, on Talazoparib vs Chemotherapy for Breast Cancer: Results From the EMBRACA Trial

Hope S. Rugo, MD, on Talazoparib for Advanced Solid Tumors: Reduced Hospitalization and Supportive Care

Barbara DeVivo, PhD, MBA, on Tumor Boards: The Influence of Social Hierarchy on Cancer Treatment Decision-Making

Pam Baker DeGuzman, PhD, on Assessing Distress During Telemedicine Visits With Rural Survivors of Head and Neck Cancer

Christopher D'Avella, MD, on Utilizing a Specialized Urgent Care Center for Patients With Cancer


COVID-19 and Cancer Care

Miguel-Angel Perales, MD, and Syed A. Abutalib, MD, on Bone Marrow Transplants During the COVID-19 Pandemic

Mikkael A. Sekeres, MD, on Cancer Treatment in the Age of COVID-19: Personal Observations

William Dale, MD, PhD, on Best Practices for Special Populations During the COVID-19 Pandemic

Laura C. Michaelis, MD: In My Experience Question 1

Laura C. Michaelis, MD: In My Experience Question 2

Laura C. Michaelis, MD: In My Experience Question 3

Laura C. Michaelis, MD: In My Experience Question 4

Laura C. Michaelis, MD: In My Experience Question 5

Mehdi Hamadani, MD: In My Experience Question 1

Mehdi Hamadani, MD: In My Experience Question 2

Mehdi Hamadani, MD: In My Experience Question 3

Mehdi Hamadani, MD: In My Experience Question 4

Mehdi Hamadani, MD: In My Experience Question 5

Mehdi Hamadani, MD: In My Experience Question 6

Saad Z. Usmani, MD: In My Experience Question 1

Saad Z. Usmani, MD: In My Experience Question 2

Saad Z. Usmani, MD: In My Experience Question 3

Saad Z. Usmani, MD: In My Experience Question 4

Saad Z. Usmani, MD: In My Experience Question 5

Rafal Dziadziuszko, MD, PhD, on Using Telemedicine During the Pandemic: Experience in Poland

Rafal Dziadziuszko, MD, PhD, on Helping Ease Oncology Patients’ Fears of Contracting COVID-19

Jacek Jassem, MD, PhD, on Fighting COVID-19 and Cancer: The View From Poland

Paolo A. Ascierto, MD, on Cancer Treatment During the COVID-19 Pandemic: The View From Southern Italy

Joseph C. Alvarnas, MD, on the Increased Risk of Side Effects for Patients With Cancer and COVID-19

Giorgio V. Scagliotti, MD, PhD, on the Oncoming Waves of COVID-19: Italy’s Experience

Giorgio V. Scagliotti, MD, PhD, on the Ongoing Battle Against COVID-19: Update From Italy

Eduardo L. Cazap, MD, PhD, on COVID-19: The View From South America

Derek Raghavan, MD, PhD, on COVID-19 and Cancer Care: The View From North Carolina

Nancy E. Davidson, MD, on COVID-19 and Cancer Care: Thoughts From the Seattle Epicenter

William A. Wood, MD, MPH, on the New ASH Research Collaborative Data Hub COVID-19 Registry for Hematologic Malignancy

Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials

Giuseppe Curigliano, MD, PhD, on How COVID-19 Is Affecting Cancer Care: The View From Italy

Karen E. Knudsen, PhD, MBA, on Delivering Cancer Care During the COVID-19 Pandemic: Report From Philadelphia


2020 Multidisciplinary Head and Neck Cancers Symposium

Francis P. Worden, MD, on the Role of Induction Chemotherapy in Laryngeal Preservation

Carryn M. Anderson, MD, on Reducing Severe Oral Mucositis and Its Effect on Patient Outcomes

Nadeem Riaz, MD, on Established and Emerging Biomarkers for Immunotherapy in Head and Neck Cancer

Assuntina G. Sacco, MD, on Head and Neck Squamous Cell Carcinoma: Trial Results on Pembrolizumab and Cetuximab

Jill Gilbert, MD, on HPV-Associated Oropharyngeal Cancer: Challenges in De-intensifying Systemic Therapies

David Adelstein, MD, on Guidelines for Treating HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Gopal K. Bajaj, MD, MBA, on Reducing Opioid Use in Patients With Head and Neck Cancer Undergoing Radiotherapy

Jonathan D. Schoenfeld, MD, MPH, on Oral Cavity Cancer: Neoadjuvant Nivolumab With or Without Ipilimumab

Jared Weiss, MD, on Squamous Cell Carcinoma of the Head and Neck: When Standard Therapy is Contraindicated

Sue Sun Yom, MD, PhD, on HPV-Associated Oropharyngeal Cancer: Challenges in De-intensifying Radiation Therapy


2020 Genitourinary Cancers Symposium

Jonathan E. Rosenberg, MD, on Locally Advanced or Metastatic Urothelial Carcinoma: Enfortumab Vedotin Plus Pembrolizumab

Syed A. Hussain, MD, on Muscle-Invasive Bladder Cancer: NEO-BLADE Trial of Nintedanib Plus Chemotherapy

David P. Dearnaley, MD, on Prostate Cancer: Conventional vs Hypofractionated High-Dose Radiotherapy

Julie N. Graff, MD, on Castration-Resistant Prostate Cancer: Results From KEYNOTE-199 on Pembrolizumab Plus Enzalutamide

Ziad Bakouny, MD, on Metastatic Kidney Cancer: Defining the Role of Cytoreductive Nephrectomy

Toni K. Choueiri, MD, on an HIF2A Inhibitor for Advanced Clear Cell RCC

Neeraj Agarwal, MD, on Castration-Resistant Prostate Cancer: Results From the COSMIC-021 Study of Cabozantinib and Atezolizumab

Maha Hussain, MD, on Next-Generation Sequencing of Prostate Tumor Tissue: Results From the PROfound Study

Nicholas D. James, PhD, MBBS, on Bladder Cancer: Cetuximab With Chemoradiotherapy

Karim Fizazi, MD, PhD, on Prostate Cancer: Pain and Quality of Life in Patients Receiving Cabazitaxel vs Abiraterone or Enzalutamide

Thomas Powles, MD, PhD, on Adding Radiation to Immunotherapy for RCC: Improving Systemic Control Through Local Therapy

Nizar M. Tannir, MD, on Nivolumab/Ipilimumab vs Sunitinib in Advanced Kidney Cancer

Hannah L. Rush, MBChB, on Prostate Cancer: Comparing Quality of Life in Patients Receiving Docetaxel or Abiraterone

Toni K. Choueiri, MD, on COSMIC-313: Cabozantinib in Combination With Nivolumab/Ipilimumab in RCC

Ziad Bakouny, MD, on Sarcomatoid and Rhabdoid RCC: Potential Determinants of Poor Prognosis and Treatment Response

Nicholas D. James, PhD, MBBS, on Adding Abiraterone to Hormone Therapy in Prostate Cancer: STAMPEDE Trial on Cost-Effectiveness


2020 ASCO-SITC Clinical Immuno-Oncology Symposium

Elizabeth A. Mittendorf, MD, PhD, on Mobilizing the Immune System to Treat Select Solid Tumors

Dario Vignali, PhD, on Immune Resistance Mechanisms in Cancer

Luis I. Ruffolo, MD, on Pancreatic Cancer: Augmenting Immunotherapy With Antibody Blockade of Semaphorin 4D

Philippa G. Corrie, PhD, on Patient Outcomes in Melanoma After Immune Checkpoint Inhibition

Martin McCarter, MD, on Refinement of Surgical Treatment: Expert Perspective on ASCO’s 2020 Advance of the Year

Jacob J. Adashek, DO, on Immunoregulatory Molecules, Cancer Genes, and Therapeutic Insights

Kevin Tyan on Colitis Induced by Immune Checkpoint Inhibitors: Potential Preventive Strategy

Christopher B. Cole, MD, PhD, on Ovarian Cancer: First-in-Human Study of Interferon-Activated Autologous Monocytes

John N. Lukens, MD, on Advanced Melanoma: Antibiotics, Survival, and Colitis in Patients Receiving Immunotherapy

Jarrett Failing, MD, on Human Leukocyte Antigen Expression in NSCLC With Brain Metastases

Advertisement

Advertisement



Jan
23
Today In Oncology
New Study Finds Suspicious Lesions on Breast MRI in Neoadjuvant Setting Are Unlikely to Be Malignant
IMpower133 Update Atezolizumab Plus Carboplatin/Etoposide for Extensive-Stage Small Cell Lung Cancer
Belantamab Mafodotin-blmf in Multiple Myeloma Number of Prior Treatments No Hindrance to Efficacy
Multiancestry Meta-analysis of Prostate Cancer Genetics
Final Overall Survival Results of the IDEA Collaboration 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer
View More 
Advertisement
© 2021 HSP News Service, L.L.C.
Designed by Harborside